Hartwig Medical Foundation welcomes Eliëtte Vaal to its Supervisory Board
Hartwig Medical Foundation (Hartwig) has welcomed Eliëtte Vaal as a new member of its Supervisory Board. Her appointment reflects Hartwig’s proactive response to developments in legislation and regulations concerning the (re)use of sensitive patient data to improve cancer care. Eliëtte brings extensive expertise in data, AI, and privacy law, which is a valuable addition to the Board.
Her arrival coincides with the departure of Guido Derckx, partner at Loyens & Loeff, who stepped down on 1 April after serving on the Board since Hartwig’s founding in 2015. His commitment and legal insight have been instrumental in strengthening the professionalism of the Supervisory Board. Hartwig expresses its sincere gratitude for his many years of dedicated service.
Data-driven cancer care
Constantijn van Oranje, chair of Hartwig’s Supervisory Board: ‘Hartwig has evolved from a high-tech laboratory into a data- and software-driven organization, leveraging sensitive patient data to advance cancer care. This transformation calls for specific expertise on our Supervisory Board. We are therefore pleased to welcome Eliëtte Vaal. Her legal knowledge and experience in complex data privacy and regulatory matters will be of great value in this phase. It is essential to achieve our goal: better, data-driven cancer care for every patient.’
Building trust
Eliëtte Vaal: ‘It is a great opportunity to apply my legal expertise to support Hartwig’s ambitions and the legal challenges it faces, and to contribute to improving care for cancer patients. The responsible and secure use of data is crucial for personalized treatments and for accelerating research. By collecting, using, and sharing patient data in a responsible and transparent way, we can not only enhance the effectiveness of treatments, but also strengthen patients’ trust in data-driven healthcare.’
About Eliëtte Vaal
Eliëtte Vaal is a partner and co-founder of The Data Lawyers, specializing in AI, privacy, and IT law. She advises and litigates on data-related legal matters and has broad experience within the healthcare sector. Eliëtte also serves on the European Advisory Board of the International Association of Privacy Professionals (IAPP), is a member of the Board of Directors of claim foundation CUIC, an Arbiter at SGOA, and a member of the Advisory Board of the Privacy First Foundation.
All news
Also read
Collaboration for future-proof diagnostics and to accelerate research
Complete analysis of the DNA of children with cancer offers many possibilities. It maps out all possible targeted treatment options …
To study rare cancers, collaboration is key
In honor of Rare Disease Day on February 28th, we spoke with Professor Stefan Fröhling about his research on rare …
Automatically the right trial and treatment with ACTIN: A new step in cancer care
Imagine you have a patient with cancer sitting across from you: can’t be cured, but he is determined to try …
A complete genetic analysis should be part of the standard diagnostics for every patient with cancer who is eligible for treatment. WGS contributes to better, coordinated treatment advice. In this way, we reduce over- and under-treatment, while making healthcare more cost-effective and keeping it affordable.